Form 4: Corcept Therapeutics Officer Exercises Options and Sells Shares
SEC Form 4
Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options and sold shares on May 1, 2025, according to a Form 4 filing.
Summary
- On May 1, 2025, Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options to acquire 9,350 shares of common stock at a price of $13.56 per share.
- Simultaneously, Lyon sold 9,350 shares of common stock at a weighted average price of $71.9552 per share, with prices ranging from $71.88 to $72.10.
- Following these transactions, Lyon directly owns 9,009 shares of Corcept Therapeutics common stock, which includes 1,232 shares underlying unvested restricted stock awards granted on June 3, 2024, 372 shares granted on September 3, 2024, 215 shares granted on December 2, 2024, and 216 shares granted on March 3, 2025.
- Lyon also holds options to purchase 46,571 shares of common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard insider transaction disclosure.
Industry Context
This filing is a routine disclosure of insider trading activity. It's common for executives to exercise stock options and sell shares for personal financial management.
Key Dates
| Date | Description |
|---|---|
| 08/30/2024 | Reporting Person adopted a 10b5-1 plan |
| 06/03/2024 | Grant date of 1,232 unvested restricted stock awards |
| 09/03/2024 | Grant date of 372 unvested restricted stock awards |
| 12/02/2024 | Grant date of 215 unvested restricted stock awards |
| 03/03/2025 | Grant date of 216 unvested restricted stock awards |
| 05/01/2025 | Date of stock option exercise and share sale |
| 05/05/2025 | Date of Form 4 filing |
| 02/07/2030 | Expiration date of stock options |
Keywords
Form 4, insider trading, stock options, share sale, Corcept Therapeutics, CORT, Lyon, Joseph Douglas Lyon
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.